
    
      Tolerability, safety, and pharmacokinetics (PK) of URC102 will be assessed after 7-day
      repeated oral dose in healthy adult Korean males. In addition, pharmacodynamic (PD) response
      of blood and urinary uric acid levels will be assessed.
    
  